# A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

> **NCT05813665** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 146 (estimated)

## Conditions studied

- Giant Cell Tumor of Bone

## Interventions

- **DRUG:** Narlumosbart
- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT05813665
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-04
- **Primary completion:** 2028-06
- **Final completion:** 2028-09
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813665, "A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05813665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*